Wedbush Issues Negative Estimate for RARE Earnings

Key Points

• Wedbush has lowered its Q3 2025 earnings estimate for Ultragenyx Pharmaceutical to ($1.38) per share, down from a prior estimate of ($1.36), while maintaining a "Neutral" rating on the stock with a price target of $34.00.
• The company reported a negative net margin of 87.34% and a return on equity of -237.48%, with revenue of $166.50 million for the last quarter, exceeding analyst expectations.
• Insiders at Ultragenyx Pharmaceutical have sold a total of 10,456 shares of stock in the last three months, with corporate insiders owning 5.50% of the total shares outstanding.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Equities researchers at Wedbush cut their Q3 2025 earnings estimates for shares of Ultragenyx Pharmaceutical in a research note issued to investors on Tuesday, October 14th. Wedbush analyst L. Chico now anticipates that the biopharmaceutical company will post earnings of ($1.38) per share for the quarter, down from their previous estimate of ($1.36). Wedbush currently has a "Neutral" rating and a $34.00 price objective on the stock. The consensus estimate for Ultragenyx Pharmaceutical's current full-year earnings is ($5.18) per share. Wedbush also issued estimates for Ultragenyx Pharmaceutical's Q4 2025 earnings at ($1.46) EPS, FY2025 earnings at ($5.58) EPS, Q2 2026 earnings at ($1.15) EPS, Q4 2026 earnings at ($1.00) EPS, FY2026 earnings at ($4.43) EPS, FY2027 earnings at ($3.29) EPS and FY2028 earnings at $0.05 EPS.

Several other equities research analysts have also commented on the stock. Guggenheim reiterated a "buy" rating and issued a $64.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday, June 20th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, October 8th. Morgan Stanley decreased their price objective on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating on the stock in a research report on Monday, July 14th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $105.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday, September 5th. Finally, HC Wainwright reiterated a "buy" rating and issued a $80.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, September 9th. Eleven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $81.50.

Ultragenyx Pharmaceutical Stock Up 5.5%

Ultragenyx Pharmaceutical stock opened at $33.43 on Thursday. Ultragenyx Pharmaceutical has a 52 week low of $25.81 and a 52 week high of $57.99. The firm's 50-day simple moving average is $29.98 and its 200 day simple moving average is $32.94. The firm has a market capitalization of $3.22 billion, a PE ratio of -6.05 and a beta of 0.21.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) EPS for the quarter, topping the consensus estimate of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. The company had revenue of $166.50 million for the quarter, compared to analyst estimates of $161.37 million. During the same period in the previous year, the firm earned ($1.52) EPS. The business's revenue was up 13.2% on a year-over-year basis. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS.

Insider Activity

In other news, EVP Karah Herdman Parschauer sold 2,450 shares of the company's stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $31.17, for a total transaction of $76,366.50. Following the completion of the transaction, the executive vice president owned 73,271 shares of the company's stock, valued at $2,283,857.07. This represents a 3.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Howard Horn sold 7,942 shares of the company's stock in a transaction dated Monday, October 13th. The shares were sold at an average price of $31.51, for a total transaction of $250,252.42. Following the transaction, the chief financial officer directly owned 98,227 shares of the company's stock, valued at approximately $3,095,132.77. This represents a 7.48% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 10,456 shares of company stock valued at $328,486 in the last three months. 5.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Fred Alger Management LLC increased its stake in shares of Ultragenyx Pharmaceutical by 12.5% during the 1st quarter. Fred Alger Management LLC now owns 524,637 shares of the biopharmaceutical company's stock valued at $18,997,000 after acquiring an additional 58,372 shares during the last quarter. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Ultragenyx Pharmaceutical during the 2nd quarter valued at about $353,000. Assenagon Asset Management S.A. increased its position in Ultragenyx Pharmaceutical by 439.0% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,163,755 shares of the biopharmaceutical company's stock worth $42,314,000 after purchasing an additional 947,865 shares in the last quarter. Millennium Management LLC increased its position in Ultragenyx Pharmaceutical by 2.2% during the 1st quarter. Millennium Management LLC now owns 712,393 shares of the biopharmaceutical company's stock worth $25,796,000 after purchasing an additional 15,157 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in Ultragenyx Pharmaceutical by 18.0% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,652 shares of the biopharmaceutical company's stock worth $133,000 after purchasing an additional 557 shares in the last quarter. Institutional investors and hedge funds own 97.67% of the company's stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.